Life Molecular Imaging (LMI) and PharmaLogic Holdings Corp. (PharmaLogic), a contract development and manufacturing organization (CDMO) and radiopharmacy solutions provider, have announced the expansion of their strategic partnership and licensing agreement to produce and distribute Neuraceq from PharmaLogic's PET radiopharmaceutical manufacturing facility located near Salt Lake City, Utah. The first commercial doses were made available on April 23, 2025.

Neuraceq is an FDA-approved radioactive diagnostic agent for the detection of amyloid plaques in the brain of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.

Neuraceq is used in clinical routine and is also a powerful diagnostic tool for the appropriate characterisation of patients assessed for treatment eligibility with newly approved anti-amyloid drugs, or for enrolment in clinical trials to further support drug development in neurodegenerative diseases.

Colleen Ruby, US Country Head and Chief Operating Officer, Americas and APAC Life Molecular Imaging said, “Life Molecular Imaging is pleased to expand the availability of Neuraceq to Salt Lake City, enhancing access for patients and imaging centres in this key region. This expansion reflects LMI's commitment to ensuring broad accessibility to Neuraceq, reinforcing our dedication to supporting a key step on the pathway to treatment.”